Selexipag in the management of pulmonary arterial hypertension: an update

References

• Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67–119. 26320113
   PubMed Web of Science ®Google Scholar
• Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123(2):344–350. doi:10.1378/chest.123.2.34412576350
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349. doi:10.7326/0003-4819-115-5-3431863023
   PubMed Web of Science ®Google Scholar
• Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146(6):1494–1504. doi:10.1378/chest.13-301424992469
   PubMed Web of Science ®Google Scholar
• Mercurio V, Diab N, Peloquin G, et al. Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. Eur Respir J. 2018;52(4):pii: 1800497. doi:10.1183/13993003.00497-2018
   Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142(2):448–456. doi:10.1378/chest.11-146022281797
   PubMed Web of Science ®Google Scholar
• Gräf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9(1):1416. doi:10.1038/s41467-018-03672-429650961
   PubMed Web of Science ®Google Scholar
• Guignabert C, Tu L, Girerd B, et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest. 2015;147(2):529–537. doi:10.1378/chest.14-086225644906
   PubMed Web of Science ®Google Scholar
• Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat. 2015;120:56–71. doi:10.1016/j.prostaglandins.2015.04.00725917921
   PubMed Web of Science ®Google Scholar
• Le Hiress M, Tu L, Ricard N, et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/CD74 complex. Am J Respir Crit Care Med. 2015;192(8):983–997. doi:10.1164/rccm.201402-0322OC26203495
   PubMed Web of Science ®Google Scholar
• Nicolls MR, Voelkel NF. The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2017;195(10):1292–1299. doi:10.1164/rccm.201608-1630PP27786553
   PubMed Web of Science ®Google Scholar
• Boucherat O, Peterlini T, Bourgeois, et al. Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;198(1):90–103. doi:10.1164/rccm.201708-1751OC29394093
   PubMed Web of Science ®Google Scholar
• Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352(9129):719–725.9729004
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):pii: 1700889. doi:10.1183/13993003.00711-2017
   Web of Science ®Google Scholar
• Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):pii: 1700740. doi:10.1183/13993003.00711-2017
   Web of Science ®Google Scholar
• National audit of pulmonary hypertension Great Britian 2017–2018. Available from: https://files.digital.nhs.uk/C6/A3B336/National%20Audit%20of%20Pulmonary%20Hypertension%209th%20Annual%20Report%20-%20Main%20Report%20V02.pdf. Accessed 72, 2019.
   Google Scholar
• Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–4181. doi:10.1093/eurheartj/ehx25728575277
   PubMed Web of Science ®Google Scholar
• Fujino H, Murayama T, Regan JW. Assessment of constitutive activity in E-type prostanoid receptors. Methods Enzymol. 2010;484:95–107. doi:10.1016/B978-0-12-381298-8.00005-821036228
   PubMed Web of Science ®Google Scholar
• Benyahia C, Boukais K, Gomez I, et al. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. Prostaglandins Other Lipid Mediat. 2013;107:48–55. doi:10.1016/j.prostaglandins.2013.07.00123850788
   PubMed Web of Science ®Google Scholar
• Patel JA, Shen L, Hall SM, et al. Prostanoid EP2 receptors are up-regulated in human pulmonary arterial hypertension: a key anti-proliferative target for treprostinil in smooth muscle cells. Int J Mol Sci. 2018;19(8):pii: E2372. doi:10.3390/ijms19082372
   Web of Science ®Google Scholar
• Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin- induced acute pulmonary vasodilatation in primary pulmonary hypertension. Circulation. 1982;66:334–338. doi:10.1161/01.cir.66.2.3347046988
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70–75. doi:10.1056/NEJM1992070932702021603138
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301. doi:10.1056/NEJM1996020133405048532025
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925–1932. doi:10.1164/ajrccm.159.6.980405410351941
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–1226. doi:10.1152/physrev.1999.79.4.119310508233
   PubMed Web of Science ®Google Scholar
• Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24(138):621–629. doi:10.1183/16000617.0063-201526621976
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329. doi:10.1056/NEJMoa02020412151469
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–1263. doi:10.1164/rccm.200510-1659PP16946127
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691–694. doi:10.1183/09031936.06.0005790617012628
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895–1902. doi:10.1093/eurheartj/ehi09315888496
   PubMed Web of Science ®Google Scholar
• Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104:731–740. doi:10.1016/j.rmed.2010.01.00820153158
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–1502. doi:10.1016/S0735-1097(02)01786-211985913
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–2125. doi:10.1016/S0735-1097(03)00463-712821234
   PubMed Web of Science ®Google Scholar
• United Therapeutics Corporation. United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint; 2019. Available from: https://ir.unither.com/news-releases/news-release-details/united-therapeutics-announces-beat-study-esuberaprost-does-not. Accessed July 11, 2019.
   Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804. doi:10.1164/ajrccm.165.8.210610411897647
   PubMed Web of Science ®Google Scholar
• Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant. 2012;31:735–743. doi:10.1016/j.healun.2012.02.02522480725
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915–1922. doi:10.1016/j.jacc.2010.01.02720430262
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127:624–633. doi:10.1161/CIRCULATIONAHA.112.12438823307827
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144:952–958. doi:10.1378/chest.12-287523669822
   PubMed Web of Science ®Google Scholar
• United Therapeutics press release August 8th 2018. Available from: https://ir.unither.com/news-releases/news-release-details/united-therapeutics-announces-freedom-ev-study-orenitram-meets. Accessed 72, 2019.
   Google Scholar
• United Therapeutics Corporation. Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress; 2019. Available from: https://www.prnewswire.com/news-releases/survival-data-from-freedom-ev-study-of-orenitram-presented-at-the-pulmonary-vascular-research-institute-annual-world-congress-300787904.html. Accessed July 11, 2019.
   Google Scholar
• Chakinala MM, Feldman JP, Rischard F, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant. 2017;36:193–201. doi:10.1016/j.healun.2016.06.01927469018
   PubMed Web of Science ®Google Scholar
• Richter MJ, Harutyunova S, Bollmann T, et al. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant. 2018;37(10):1235–1244. doi:10.1016/j.healun.2018.06.00630293617
   PubMed Web of Science ®Google Scholar
• Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev. 2015;24(138):630–641. doi:10.1183/16000617.0067-201526621977
   PubMedGoogle Scholar
• Picken C, Fragkos KC, Eddama M, et al. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis. J Clin Med. 2019;8(4):pii: E481. doi:10.3390/jcm8040481
   Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322(3):1181–1188. doi:10.1124/jpet.107.12424817545310
   PubMed Web of Science ®Google Scholar
• Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 2015;58(18):7128–7137. doi:10.1021/acs.jmedchem.5b0069826291199
   PubMed Web of Science ®Google Scholar
• Morrison K, Studer R, Ernst R, Haag F, Kauser K, Clozel M. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther. 2012;343(3):547–555. doi:10.1124/jpet.112.19715222918043
   PubMed Web of Science ®Google Scholar
• Fuchikami C, Murakami K, Tajima K, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. Eur J Pharmacol. 2017;795:75–83. doi:10.1016/j.ejphar.2016.11.05727919660
   PubMed Web of Science ®Google Scholar
• Benyahia C, Ozen G, Orie N, et al. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents. Prostaglandins Other Lipid Mediat. 2015;121(Pt A):46–52. doi:10.1016/j.prostaglandins.2015.09.00226362969
   PubMed Web of Science ®Google Scholar
• Gatfield J, Menyhart K, Wanner D, et al. Selexipag active metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low β-arrestin recruitment and desensitization potential. J Pharmacol Exp Ther. 2017;362(1):186–199. doi:10.1124/jpet.116.23966528476928
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15(3):195–203. doi:10.1007/s40256-015-0117-425850750
   PubMed Web of Science ®Google Scholar
• Krause A, Machacek M, Lott D, Hurst N, Bruderer S, Dingemanse J. Population modeling of selexipag pharmacokinetics and clinical response parameters in patients with pulmonary arterial hypertension. CPT Pharmacometrics Syst Pharmacol. 2017;6(7):477–485. doi:10.1002/psp4.1220228556581
   PubMedGoogle Scholar
• Kaufmann P, Cruz HG, Krause A, Ulč I, Halabi A, Dingemanse J. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. Br J Clin Pharmacol. 2016;82(2):369–379. doi:10.1111/bcp.1296327062188
   PubMed Web of Science ®Google Scholar
• Gnerre C, Segrestaa J, Seeland S, et al. The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica. 2018;48(7):704–719. doi:10.1080/00498254.2017.135708828737453
   PubMed Web of Science ®Google Scholar
• Bruderer S, Okubo K, Mukai H, Mant T, Dingemanse J. Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects. Clin Ther. 2016;38(5):1228–1236. doi:10.1016/j.clinthera.2016.03.01427063071
   PubMed Web of Science ®Google Scholar
• Juif PE, Boehler M, Donazzolo Y, Bruderer S, Dingemanse J. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects. Eur J Clin Pharmacol. 2017;73(9):1121–1128. doi:10.1007/s00228-017-2282-728639119
   PubMed Web of Science ®Google Scholar
• Bruderer S, Petersen-Sylla M, Boehler M, Remeňová T, Halabi A, Dingemanse J. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2017;83(12):2778–2788. doi:10.1111/bcp.1337928715853
   PubMed Web of Science ®Google Scholar
• Janssen-Cilag Ltd. Summary of product characteristics - selexipag; 2016 [updated May, 2018]. Available from: https://www.medicines.org.uk/emc/product/2163/smpc. Accessed July 11, 2019.
   Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–880. doi:10.1183/09031936.0021371122362844
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533. doi:10.1056/NEJMoa150318426699168
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment report: uptravi (selexipag). 2016 [ updated April 1, 2016]. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003774/WC500207175.pdf. Accessed March 15, 2017.
   Google Scholar
• Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospitalisation for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4:692–699. doi:10.1161/CIRCHEARTFAILURE.110.94993321908586
   PubMed Web of Science ®Google Scholar
• Burger C, Long P, Shah M, et al. Characterisation of first-time hospitalisation in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146(5):1263–1273. doi:10.1378/chest.14-019324901386
   PubMed Web of Science ®Google Scholar
• Farber H, Miller D, McGoon M, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6 min walk test. J Heart Lung Transplant. 2015;34:362–368. doi:10.1016/j.healun.2014.08.02025312386
   PubMed Web of Science ®Google Scholar
• Zelniker T, Huscher D, Vonk-Noordengraff A, et al. The 6 min walk test as a prognostic indicator in pulmonary arterial hypertension: results from the COMPERA registry. Clinc Res Cardiol. 2018;107(6):460–470. doi:10.1007/s00392-018-1207-5
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Hoeper M, Channick R, et al. Pulmonary arterial hypertension related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71(7):752–763. doi:10.1016/j.jacc.2017.12.01029447737
   PubMed Web of Science ®Google Scholar
• Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract. 2009;15(2):116–121. doi:10.4158/EP.15.2.11619289321
   PubMed Web of Science ®Google Scholar
• Hoeper MM, McLaughlin VV, Barberá JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITIONstudy. Lancet Respir Med. 2016;4(11):894–901. doi:10.1016/S2213-2600(16)30307-127745818
   PubMed Web of Science ®Google Scholar
• Coghlan G, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018;18(1):37–47. doi:10.1007/s40256-017-0262-z29307087
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (TRITON); 2015 [updated July 10, 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02558231. Accessed July 11, 2019.
   Google Scholar
• Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8(3):413–425. doi:10.1016/j.hfc.2012.04.00122748903
   PubMed Web of Science ®Google Scholar
• Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015;192(9):1111–1117. doi:10.1164/rccm.201507-1456OC26291092
   PubMed Web of Science ®Google Scholar
• Rhee RL, Gabler NB, Praestgaard A, Merkel PA, Kawut SM. Adverse events in connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 2015;67(9):2457–2465. doi:10.1002/art.3922026016953
   PubMed Web of Science ®Google Scholar
• Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50:1602493. doi:10.1183/13993003.00711-201728818881
   PubMed Web of Science ®Google Scholar